Your email has been successfully added to our mailing list.

×
0.0597222222222223 0.0625 0.180555555555556 0.25 0.308333333333333 0.266666666666667 0.258333333333333 0.256944444444445
Stock impact report

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Precigen, Inc. (PGEN)  More Company Research Source: PR Newswire
Last precigen, inc. earnings: 3/2 04:05 pm Check Earnings Report
Impact snapshot Event time: PGEN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
PGEN alerts
from News Quantified
Opt-in for
PGEN alerts

from News Quantified
Opt-in for
PGEN alerts

from News Quantified